Actively Recruiting
Phase 1a1b Open-Label Study Evaluating Safety, Pharmacokinetics, and Activity of JUR-003 in Adult Men with Metastatic Prostate Cancer
Led by Juri Biosciences, Inc. · Updated on 2026-11-04
210
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating JUR-003, a biological drug given intravenously, in adult men with metastatic prostate cancer, including metastatic castration resistant prostate cancer, oligometastatic prostate cancer, and metastatic hormone sensitive prostate cancer. This first-in-human Phase 1a1b open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JUR-003. The study is sponsored by Juri Biosciences, Inc. and includes two parts dose escalation and dose expansion. In Part 1 Dose Escalation, participants receive varying doses of JUR-003 to determine the recommended dose for expansion RDE. In Part 2 Dose Expansion, participants receive JUR-003 at the determined RDE to further confirm safety and observe anti-tumor activity. The drug is administered intravenously throughout the study, which follows a sequential study model without randomization or blinding. Participants will be monitored for safety and tolerability over 2 years and for pharmacokinetics characterization over the same period. The recommended dose for expansion will be determined within the first year. The study includes regular assessments for tumor response using RECIST and PCWG criteria. Participation is expected to last until study completion in June 2030, with ongoing monitoring of treatment effects and safety.
CONDITIONS
Brief Title
JUR-003 in Adult Patients With Metastatic Prostate Cancer
Research Team
L
Lisa Knapp
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here